Elanco completes acquisition of Bayer’s Animal Health business unit
The divestment of the Animal Health business is the largest transaction in a series of portfolio measures Bayer initiated in November 2018.
Bayer has completed the sale of its Animal Health business unit to U.S. Company Elanco Animal Health Incorporated. The companies had signed an agreement to this effect in August of last year. The transaction was completed after fulfilment of the closing conditions, including the receipt of regulatory approvals.
Upon closing of the transaction, Bayer received 5.17 billion U.S. dollars (before tax) in cash after deduction of customary purchase price adjustments, along with 72.9 million shares of Elanco Animal Health common stock, corresponding to 15.5 percent of the U.S. company’s outstanding stock. Bayer maintains its intention to divest the stake in Elanco in due course. The shares are subject to certain retention periods until mid-2021.
The divestment of the Animal Health business is the largest transaction in a series of portfolio measures Bayer initiated in November 2018. The company has already completed the sale of the Coppertone™ and Dr Scholl’s™ consumer health brands and of its 60 percent stake in German site services provider Currenta. Bayer’s former Animal Health business has about 4,400 employees and achieved sales of 1.57 billion euros in 2019. It develops and markets innovative products and solutions for the prevention and treatment of diseases in companion and farm animals.
“We would like to thank the employees of Animal Health for their long-standing commitment and the success this has brought for Bayer. In Elanco we’ve found a strong new owner for our Animal Health business. This transaction creates one of the global animal health leaders,” said Werner Baumann, Chairman of the Board of Management of Bayer AG. “We’ve also succeeded in safeguarding the interests of the workforce.” Under the agreement with Elanco, all Bayer Animal Health employees will have at least one year of employment protection against unilateral termination with similar and no less favourable benefits in the aggregate.